J&J Urges Pa. Appeals Court To Undo $2.5M Risperdal Verdict
Law360 (August 8, 2018, 5:56 PM EDT) -- A Johnson & Johnson unit pushed a Pennsylvania appeals court on Wednesday to jettison a $2.5 million verdict on grounds that a trial judge improperly barred it from using a scientific article to challenge an expert’s opinion that the antipsychotic drug Risperdal caused an adolescent boy to grow breasts.
Robert Heim, an attorney with Dechert LLP representing J&J subsidiary Janssen Pharmaceuticals Inc., said the judge’s decision to bar the so-called learned treatise had allowed the expert’s opinion to go uncountered during cross-examination.
“Instead of being able to confront the medical causation expert with an article that absolutely contradicted and undermined his...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!